S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Bezos and Gates Invest in Search for Tech's Best-Kept Secret (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Game-Changing Cancer Tech Nears FDA Completion (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Game-Changing Cancer Tech Nears FDA Completion (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Bezos and Gates Invest in Search for Tech's Best-Kept Secret (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Game-Changing Cancer Tech Nears FDA Completion (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Game-Changing Cancer Tech Nears FDA Completion (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Bezos and Gates Invest in Search for Tech's Best-Kept Secret (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Game-Changing Cancer Tech Nears FDA Completion (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Game-Changing Cancer Tech Nears FDA Completion (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Bezos and Gates Invest in Search for Tech's Best-Kept Secret (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Game-Changing Cancer Tech Nears FDA Completion (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Game-Changing Cancer Tech Nears FDA Completion (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
NASDAQ:RCM

R1 RCM (RCM) Stock Price, News & Analysis

$14.05
-0.34 (-2.36%)
(As of 02/29/2024 ET)
Today's Range
$13.96
$14.65
50-Day Range
$9.11
$14.58
52-Week Range
$8.87
$18.70
Volume
5.02 million shs
Average Volume
4.59 million shs
Market Capitalization
$5.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.53

R1 RCM MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.81 Rating Score
Upside/​Downside
26.4% Upside
$17.76 Price Target
Short Interest
Bearish
19.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
0.55mentions of R1 RCM in the last 14 days
Based on 52 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
155.56%
From $0.09 to $0.23 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.77 out of 5 stars

Business Services Sector

16th out of 310 stocks

Management Services Industry

1st out of 5 stocks


RCM stock logo

About R1 RCM Stock (NASDAQ:RCM)

R1 RCM Inc. provides technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and physician groups. It offers end-to-end revenue cycle management (RCM) services, which address the spectrum of revenue cycle challenges faced by healthcare providers. The company provides modular services, including physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. R1 RCM Inc. was founded in 2003 and is headquartered in Murray, Utah.

RCM Stock Price History

RCM Stock News Headlines

Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
What Makes R1 RCM (RCM) a Lucrative Investment?
TD Cowen Keeps Their Buy Rating on R1 RCM (RCM)
Game-Changing Cancer Tech Nears FDA Completion
In the world of tech advancements, a new player could outshine even AI. It's a revolutionary technology with the aim of transforming cancer detection. Imagine the leap from basic reading glasses to cutting-edge VR; that's the scale of innovation we're talking about. FDA review is in its final stages and it could become the gold standard before we know it.
Assessing R1 RCM: Insights From 10 Financial Analysts
R1 RCM Inc. (NASDAQ:RCM) Q4 2023 Earnings Call Transcript
Q4 2023 R1 RCM Inc Earnings Call
R1 RCM Reports Fourth Quarter and Full Year 2023 Results
SVB Leerink Initiates Coverage on R1 RCM (NASDAQ:RCM)
R1 RCM just downgraded at Deutsche Bank, here's why
R1 RCM Hold Rating Justified Amid Buyout Proposal and Market Dynamics
Truist Financial Reaffirms Their Buy Rating on R1 RCM (RCM)
What Wall Street expects from R1 RCM's earnings
R1 RCM Holders Discuss Take Private of Health-Care IT Firm
See More Headlines
Receive RCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for R1 RCM and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/16/2023
Today
2/29/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Management services
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:RCM
CUSIP
00438V10
Employees
27,800
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$17.76
High Stock Price Target
$22.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+24.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
16 Analysts

Profitability

Net Income
$-63,300,000.00
Pretax Margin
0.93%

Debt

Sales & Book Value

Annual Sales
$2.25 billion
Cash Flow
$0.66 per share
Book Value
$6.56 per share

Miscellaneous

Free Float
264,164,000
Market Cap
$5.89 billion
Optionable
Optionable
Beta
0.74

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report














RCM Stock Analysis - Frequently Asked Questions

Should I buy or sell R1 RCM stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RCM shares.
View RCM analyst ratings
or view top-rated stocks.

What is R1 RCM's stock price target for 2024?

16 brokers have issued twelve-month target prices for R1 RCM's shares. Their RCM share price targets range from $11.00 to $22.00. On average, they predict the company's stock price to reach $17.76 in the next twelve months. This suggests a possible upside of 26.4% from the stock's current price.
View analysts price targets for RCM
or view top-rated stocks among Wall Street analysts.

How have RCM shares performed in 2024?

R1 RCM's stock was trading at $10.57 at the start of the year. Since then, RCM stock has increased by 32.9% and is now trading at $14.05.
View the best growth stocks for 2024 here
.

When is R1 RCM's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our RCM earnings forecast
.

How were R1 RCM's earnings last quarter?

R1 RCM Inc. (NASDAQ:RCM) issued its quarterly earnings results on Thursday, February, 16th. The healthcare provider reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.06. The healthcare provider had revenue of $532.80 million for the quarter, compared to analysts' expectations of $519.28 million. R1 RCM had a trailing twelve-month return on equity of 0.12% and a net margin of 0.15%. The company's revenue for the quarter was up 33.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.11 EPS.

What guidance has R1 RCM issued on next quarter's earnings?

R1 RCM updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.6 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion.

What is Joseph Flanagan's approval rating as R1 RCM's CEO?

253 employees have rated R1 RCM Chief Executive Officer Joseph Flanagan on Glassdoor.com. Joseph Flanagan has an approval rating of 70% among the company's employees.

What other stocks do shareholders of R1 RCM own?

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

Who are R1 RCM's major shareholders?

R1 RCM's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.62%), Capital International Investors (1.99%), Voss Capital LLC (1.70%), Norges Bank (0.96%), P2 Capital Partners LLC (0.84%) and Dimensional Fund Advisors LP (0.67%). Insiders that own company stock include Achi Series Lllp Tcp-Asc, Alex Mandl, Gary Steven Long, John B Henneman III, John M Sparby, Joseph Gerard Flanagan, Lee Rivas and Richard B Jr Evans.
View institutional ownership trends
.

How do I buy shares of R1 RCM?

Shares of RCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does R1 RCM have any subsidiaries?
The following companies are subsidiares of R1 RCM: Accretive Health Mauritius Inc., Cerner RevWorks, Clearsight Intermediate Holdings Inc., Cloudmed, Flare Capital Partners Investment Company, Intermedix, Intermedix ARM LLC, Intermedix Corporation, Intermedix Holdings Inc., Intermedix Lietuva UAB, Intermedix Midco Inc., Intermedix Office Based LLC, Intermedix Staffing Inc., Medical Consultants Inc., Practice Support Resources LLC, Project Links Parent Inc., Project Roadrunner Merger Sub Inc., Project Roadrunner Parent Inc., R1 RCM Global Private Limited, R1 RCM India Private Limited, Rover16 Inc., SCHEDULING.COM INC., SCI Solutions, Tonic Health LLC, VisitPay, cGate Health Inc., and iVinci Partners LLC.
Read More
This page (NASDAQ:RCM) was last updated on 3/1/2024 by MarketBeat.com Staff